Q-omics provides the consensus-scored CBX1P4 profile across patient tissues and cancer cell-line models. CBX1P4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CBX1P4 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, CBX1P4 RNA expression shows 11,138 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where CBX1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX1P4 survival associations across molecular data types. CBX1P4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX1P4 RNA expression–survival associations across cancer types. High CBX1P4 expression shows unfavorable associations in STAD, LUAD and KICH, but favorable associations in KIRP, HNSC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for CBX1P4 RNA expression.
This table summarizes CBX1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CBX1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX1P4 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in PRAD, KIRC and LIHC. The KICH box plot shows higher CBX1P4 RNA expression in normal versus tumor tissue (log2 FC = −0.158, t-test p < 0.001).
This table shows molecular features associated with CBX1P4 in patient tissues and cancer cell lines. In patient samples, CBX1P4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
